According to the sources provided, generic varenicline, which is the generic version of the smoking cessation drug Chantix, has been approved by the FDA and is expected to be launched in the market. However, the exact launch date may vary depending on factors such as manufacturing and distribution timelines.

The first source, DrugPatentWatch, provides information on the patent status of drugs. It confirms that the patent for Chantix, the brand name version of varenicline, has expired. This indicates that generic versions of varenicline can now be produced and marketed.

The second source, Formulary Watch, reports that the FDA has approved a generic version of Chantix. However, it does not mention a specific launch date for the generic drug.

The third source, GoodRx, provides information on the cost and availability of medications. It mentions that generic versions of Chantix are available and can be purchased at a lower cost compared to the brand name version. This suggests that the generic varenicline has already been launched and is available for purchase.

In conclusion, based on the provided sources, it can be inferred that generic varenicline has been approved by the FDA and is either already available in the market or will be launched soon. However, the exact launch date may vary and it is recommended to check with local pharmacies or healthcare providers for the most up-to-date information.

Sources:
[1] DrugPatentWatch: https://www.drugpatentwatch.com/p/tradename/VARENICLINE
[2] Formulary Watch: https://www.formularywatch.com/view/fda-approves-generic-of-chantix-pfizer-s-smoking-cessation-drug
[3] GoodRx: https://www.goodrx.com/chantix/chantix-generic-cost-how-to-save-smoking-cessation